ArticleClinical and experimental dermatology2022
Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Article in Clinical and experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 92 citations in OpenAlex.
- Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.Acta dermato-venereologica · 2023Trial
- Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis.International journal of dermatology · 2026Article
- Efficacy and Safety of Icotrokinra (an Interleukin-23 Inhibitor) in the Management of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.JMA journal · 2026Article
- Effectiveness of Guselkumab for the Treatment of Moderate-to- Severe Psoriasis in Elderly Patients: A Retrospective, Real-World Multicenter Study in the Lazio Region.Clinics and practice · 2026Article
- Real-World Use of Biologic Therapy in Elderly Patients with Moderate-to-Severe Psoriasis: A Retrospective Single-Center Study.Medicina (Kaunas, Lithuania) · 2026Article
- Efficacy and Safety of Tildrakizumab in Elderly Patients With Psoriasis: A Narrative Review.The Journal of clinical and aesthetic dermatology · 2026Review
- Efficacy and Safety of Guselkumab for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Dermatology practical & conceptual · 2026Review
- Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.Dermatology and therapy · 2026Review
- Biologic Treatment in Elderly Patients with Psoriasis: Focus on Safety and Adherence.Dermatology practical & conceptual · 2026Article
- IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026Review
- Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.Journal of clinical medicine · 2025Article
- Systemic Biologic Treatment for Psoriasis in Elderly Patients.Journal of clinical medicine · 2025Article
- Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use.Life (Basel, Switzerland) · 2025Article
- Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.Psoriasis (Auckland, N.Z.) · 2025Article
- Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications.Frontiers in immunology · 2025Review
- Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.Psoriasis (Auckland, N.Z.) · 2025Article
- Real-World Experience of Guselkumab in the Elderly Population.Psoriasis (Auckland, N.Z.) · 2025Article
- Clinical insights into IL-23 inhibition: risankizumab for Crohn's disease through a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in gastroenterology · 2025Article
- Guselkumab - In Psoriasis and Beyond.Dermatology practical & conceptual · 2024Review
- Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region.Dermatology practical & conceptual · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElderly patients (aged ≥ 65 years) represent an increasing proportion of patients with psoriasis and 15% of these have moderate to severe disease. Biologics are being used frequently in this group of patients even though safety and efficacy data are limited. In addition, owing to anti-interleukin (IL)-23 therapies being a relatively recent option, no data have been reported about their use in elderly patients with psoriasis.
aimTo evaluate and compare the safety and efficacy of guselkumab, risankizumab and tildrakizumab in real-world practice in elderly patients.
methodsThis was a single-centre retrospective study that enrolled patients aged ≥ 65 years with moderate to severe plaque psoriasis, treated with guselkumab, risankizumab or tildrakizumab. The length of the study for each group depended on the drug (44 weeks for risankisumab, 40 weeks for guselkumab and 28 weeks for tildrakizumab, owing to its more recent availability in Italy).
resultsIn total, 34 patients were enrolled (n = 20 on guselkumab; n = 8 on risankizumab; n = 6 on tildrakizumab). At Week 4, 29.4% reached 90% improvement in Psoriasis Area and Severity Index (PASI90) and 8.8% reached 100% improvement in PASI (PASI100); at Week 28, PASI90 and PASI100 was reached by 58.8% and 29.4%, respectively. At the final follow-up (Week 40 or 44, depending on drug), data were available only for the risankizumab (Week 40) and guselkumab (Week 44) and groups, and showed that 71.4% of patients had reached PASI90 and 53.5% had reached PASI100. Four patients (11.7%) discontinued treatment. No significant differences were found between the three groups. The limitations of the study included its retrospective nature of the study, small sample size, and different numbers of patients and follow-up duration for the different groups (highest for guselkumab, lowest for tildrakizumab).
conclusionThe three anti-IL-23 therapies assessed are promising, safe and effective options in elderly patients, and there was no significant difference between them. However, more data are needed to confirm our results and to understand their role in the management of this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.